Aurinia deal with Teva keeps Lupkynis generic in check until '36
Aurinia deal with Teva keeps Lupkynis generic in check until '36
Aurinia Pharmaceuticals
AUPH $16.65 USD
Aurinia Pharmaceuticals | Services: Develops and commercializes therapies for autoimmune diseases, notably LUPKYNIS (voclosporin) - the first FDA-approved oral therapy for adult patients with active lupus nephritis | Leadership: Kevin Tang (CEO since March 2026, also Board Chair), other C-suite not publicly detailed on website | Keywords: lupus nephritis, voclosporin, autoimmune, calcineurin inhibitor, AUPH,肾脏病